Abstract
BackgroundOpen-label studies indicate that tetrabenazine (TBZ), a reversible inhibitor of the vesicular monoamine transporter type 2, is effective in reducing the chorea in patients with Huntington's disease (HD). Animal models...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Neurology, Neurosurgery & Psychiatry
Paper Title
Journal
Date
